You have accessJournal of UrologyProstate Cancer: Markers (I)1 Apr 20132138 CIRCULATING TUMOR CELLS (CTCS) ARE DETECTABLE IN PATIENTS WITH HIGH-RISK, LOCALIZED PROSTATE CANCER THROUGH USE OF THE CELLSEARCH PLATFORM Sumanta Pal, Clayton Lau, Miaoling He, Jennifer Linehan, Timothy Wilson, Przemyslaw Twardowski, Michael Nazmy, Mark Kawachi, Alejandra Torres, Courtney Carmichael, Yun Yen, Marcin Kortylewski, and Jeremy Jones Sumanta PalSumanta Pal Duarte, CA More articles by this author , Clayton LauClayton Lau Duarte, CA More articles by this author , Miaoling HeMiaoling He Duarte, CA More articles by this author , Jennifer LinehanJennifer Linehan Duarte, CA More articles by this author , Timothy WilsonTimothy Wilson Duarte, CA More articles by this author , Przemyslaw TwardowskiPrzemyslaw Twardowski Duarte, CA More articles by this author , Michael NazmyMichael Nazmy Duarte, CA More articles by this author , Mark KawachiMark Kawachi Duarte, CA More articles by this author , Alejandra TorresAlejandra Torres Duarte, CA More articles by this author , Courtney CarmichaelCourtney Carmichael Duarte, CA More articles by this author , Yun YenYun Yen Duarte, CA More articles by this author , Marcin KortylewskiMarcin Kortylewski Duarte, CA More articles by this author , and Jeremy JonesJeremy Jones Duarte, CA More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.2047AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Enumeration of circulating tumor cells (CTCs) using the CellSearch platform has prognostic value in patients with metastatic castration resistant prostate cancer. However, the prognostic value of CTC enumeration in high-risk, localized prostate cancer (HRLPC) remains undefined. METHODS Patients with HRLPC (defined by ≥1 of the following criteria: ≥cT3a disease, Gleason score 8-10, or PSA > 20 ng/mL) who have chosen prostatectomy for their definitive management were prospectively identified. Patients were consented to receive 4 sequential 30 mL blood draws, each collected in 10 mL CellSave tubes. The first 2 blood draws were conducted 2 weeks prior and immediately prior to surgery, while the second 2 blood draws were conducted 4-6 weeks and 3 months following surgery. Within 4 hrs of blood collection, the white blood cell (WBC) fraction was pooled and Ficoll purified. The WBC fraction was transferred to a collection tube, and CTCs were enumerated using the CellSearch system. Expression of CD133, a prostate cancer stem cell (PCSC) marker, and E-cadherin, a marker of epithelial-mesenchymal transition (EMT), was characterized using the CellSearch system in patients with detectable CTCs. RESULTS Since the initiation of the study in Nov 2011, all 36 patients have been accrued and have completed, or are soon to complete, their blood draws. Median age in the 21 patients analyzed to date was 65 (range, 51-74), and the number of patients with Gleason score 8-10, ≥cT3a disease, or PSA >20 ng/mL was 29, 2, and 7, respectively. The majority of patients had only one high-risk feature. Mean baseline PSA for the cohort was 12.24 (range, 3.4-37). CTCs were detectable in 47% of patients prior to surgery, 23% of patients at one month following surgery and 38% of patients at three months following surgery. Amongst those patients with detectable CTCs, the median count was 2 (range, 1-7). In these patients, CD133 and E-cadherin were detected in 76% and 82% of specimens assessed, respectively. We continue to follow patients using the City of Hope Prostate Cancer Database to facilitate correlations between CTC count or protein biomarker expression and biochemical progression of the cancer. CONCLUSIONS Using a modified methodology, CTC enumeration using the CellSearch platform is feasible in patients with HRLPC. Interestingly, markers of EMT and PCSCs are detectable in a high proportion of CTCs in patients with localized disease. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e875-e876 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Sumanta Pal Duarte, CA More articles by this author Clayton Lau Duarte, CA More articles by this author Miaoling He Duarte, CA More articles by this author Jennifer Linehan Duarte, CA More articles by this author Timothy Wilson Duarte, CA More articles by this author Przemyslaw Twardowski Duarte, CA More articles by this author Michael Nazmy Duarte, CA More articles by this author Mark Kawachi Duarte, CA More articles by this author Alejandra Torres Duarte, CA More articles by this author Courtney Carmichael Duarte, CA More articles by this author Yun Yen Duarte, CA More articles by this author Marcin Kortylewski Duarte, CA More articles by this author Jeremy Jones Duarte, CA More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...